David Kauffmann

Bio

David is a general partner of EEP, the chairman of CMC Biologics. Until the merger with SGS in January 2006, he also held the position of Chairman of the Management Board of Aster Cephac. Prior to EEP, from 1990, David was a partner of CAI, a North American US$150 million private equity investment fund with offices in New York, Montreal, London and Paris, investing in US$30 million plus situations. In 1992 he started CAI's European investment activities. Since then David has invested in early stage, development and replacement capital within the healthcare, telecommunications and light manufacturing industries. David is particularly interested in and has worked with a number of R&D service companies in the pharmaceutical industry. Prior to CAI, David worked for the American Express Bank in London, New York and Copenhagen, in acquisitions and trade finance. David holds an MBA from IMD in Lausanne, Switzerland, and a BSc from the Copenhagen School of Economics and Business Administration.